GW9820 is PPARα and PPARγ activator (EC50s: 0.37 μM for PPARα; 0.288 μM for PPARγ). GW9820 increases CLA-1. GW9820 can be used in the research of atherosclerosis.

L-695499 is a potent and orally active leukotriene D4 receptor antagonist. L-695499 can be used for the researches of inflammation and immunology.

CP-464709 is a Ghrelin receptor agonist that can penetrate the blood-brain barrier. CP-464709 causes an increase in blood pressure by activating pre sympathetic neurons in the spinal cord. CP-464709 causes biphasic blood pressure response when administered intravenously, while intrathecal administration only causes pressor. CP-464709 can be used for research on cardiovascular conditions.

AZD9496-O-C3-O-C3-O-C-acid is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for ERα and a PROTAC linker, which recruits E3 ligases. AZD9496-O-C3-O-C3-O-C-acid can be used for synthesis of PROTAC AZ'6421.

DTUN is a lipophilic hyponitrite radical initiator and can initiates lipid peroxidation. DTUN is a tool for research of ferroptosis.

Mesutoclax (ICP-248) (Compound 5) is a selective BCL-2 inhibitor with an IC50 of 1.54 nM. Mesutoclax has weak activity against BCL-XL (IC50: ＞1000 nM). Mesutoclax can inhibit the activity of RS4;11 cells with an IC50 of 2.75 nM. Mesutoclax can be used in the study of cancer.

SDZ89-485 is an orally active triazole antifungal agent. The peak concentration of SDZ89-485 is lower, but it exhibits a stronger anti-sporofungus effect in the mouse model than Fluconazole with a higher peak concentration. SDZ89-485 can be used in studies on anti-sporofungus.

dCDK9-202 a potent CDK9 PROTAC degrader with an DC50 value of 3.5 nM. dCDK9-202 exhibits broad-spectrum anti-tumor activity and extensively disrupts the oncogenic transcriptome. dCDK9-202 can activate Caspase-3/7, increase the level of cleaved PARP, and directly induce apoptosis of tumor cells. dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. dCDK9-202 can be used for the study of EGFR-driven cancers such as sarcoma.

ZLN005 (hydrochloride) is a peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1α) activator. ZLN005 (hydrochloride) can stimulate the expression of PGC-1α and downstream genes in skeletal muscle cells, improve glucose utilization and fatty acid oxidation. ZLN005 (hydrochloride) can increase the transcription of PGC-1α and downstream genes in skeletal muscle of diabetic db/db mice, increase fat oxidation and improve glucose tolerance, pyruvate tolerance and insulin sensitivity.

SGC0946 TFA is a selective DOT1L inhibitor with an IC50 value of 0.3 nM. By inhibiting DOT1L, SGC0946 TFA can induce G1 phase arrest, suppress cell self-renewal and metastatic potential, and induce cell differentiation in cancer cells. SGC0946 TFA can be used in the research of tumors such as leukemia and breast cancer, and also serves as a probe to further investigate the cellular mechanisms of DOT1L in normal and diseased cells.

N-19004 is a FPR1 antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa.

BMS 186318 is an HIV protease inhibitor. BMS 186318 exhibits better anti-HIV efficacy when used in combination with reverse transcriptase inhibitors such as Stavudine and other protease inhibitors such as Saquinavir. BMS 186318 can be used in antiviral research.

(R)-CMPD-39 is the R enantiomer of CMPD-39. CMPD-39 is a selective non-covalent inhibitor of the ubiquitin-specific protease USP30 (IC50 =~20 nM), with high selectivity over other DUB family members (1-100 μM). CMPD-39 inhibits the deubiquitinating activity of USP30, enhances the ubiquitination of mitochondrial proteins TOMM20 and SYNJ2BP; thus, CMPD-39 promotes phosphoubuitin accumulation, thereby accelerating mitochondrial autophagy (mitophagy) and peroxisomal autophagy (pexophagy). CMPD-39 significantly restores impaired mitochondrial function in dopaminergic neurons derived from Parkinson's disease patients.

(1R,2S)-Dihydrobupropion is a norepinephrine-dopamine reuptake inhibitor. (1R,2S)-Dihydrobupropion is one of the active metabolites of Bupropion. (1R,2S)-Dihydrobupropion can be used for the researches of neurological disease and inflammation.

P-1060 is a potassium channel opener. P-1060 can be used for the research of cardiovascular disease.

KRG-3332 (hydrochloride) is a selective α1A receptor antagonist. KRG-3332 (hydrochloride) can be used in Glaucoma.

(R,S,S)-VH032-Me-N-Boc-7-aminoheptanoic acid TFA is a conjugate of an E3 ubiquitin ligase ligand and a linker. (R,S,S)-VH032-Me-N-Boc-7-aminoheptanoic acid TFA can be used as an intermediate in the synthesis of dTAGV-1 hydrochloride

Microtubule stabilizer-1 (compound 69) is a brain-penetrant microtubule (MT) stabilizer. Microtubule stabilizer-1 increases acetylated α-tubulin (AcTub) levels and prevents the characteristic loss of neuronal MTs that is observed after incubation with Okadaic acid. Microtubule stabilizer-1 can be used for the study of Alzheimer’s disease (AD) and related neurodegenerative tauopathies.

(S,R,S)-AHPC-CO-C2-PEG-NHCO-C2-COOH is a synthetic E3 ubiquitin ligase ligand-linker conjugate that can be used to synthesize PROTACs such as dASK1-VHL.

CGP-75355 is an inhibitor of HIV-1 protease with IC50 of 26 nM. CGP-75355 is a bis(L-tert-leucine) derivative.

TP0628103 (Compound 18) TFA is a selective inhibitor of MMP-7, with the IC50 value of 0.17 nM that plays an important role in cancer and fibrosis.

ACP1-01 is a bacterial ClpP activator with EC50s of 3.4 and 2.6  μM for Neisseria meningitides ClpP (NmClpP) and Escherichia coli ClpP (EcClpP). ACP1-01 noncovalently binds to ClpP C sites and activates the protease. ACP1-01 has antibacterial activity. ACP1-01 can be used for bacterial infections research.

Ifoxetine (CGP 15210G) is an inhibitor of 5-HT reuptake. Ifoxetine specifically and selectively blocks the 5-HT reuptake in the brain without affecting the 5-HT uptake processes in the periphery (blood platelets). Ifoxetine inhibits the uptake of radiolabelled 5-HT into rat brain synaptosomes in vitro or ex vivo. Ifoxetine has antidepressant properties.

OPC-4392 is a orally active presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. OPC 4392 reverses the Reserpine-induced dopamine accumulation, inhibits Apomorphine-induced stereotypic and climbing behaviors in mouse models. OPC-4392 can be used as antipsychotic agent.

SUN-N8075 (dimethanesulfonate) is a radical scavenger with antioxidant and neuroprotective effect. SUN-N8075 (dimethanesulfonate) can inhibit apoptosis and ROS production. SUN-N8075 (dimethanesulfonate) can protect against 6-OHDA-induced cell death. SUN-N8075 (dimethanesulfonate) can be used for the research of neurological disease, such as Parkinson's disease.

Amycolatopsin C is a glycosylated macrolactone with antibacterial activity. Amycolatopsin C selectively inhibits the growth of Mycobacterium bovis (BCG) and Mycobacterium tuberculosis (H37Rv) compared to other Gram-positive and Gram-negative bacteria. Amycolatopsin C demonstrates low levels of cytotoxicity toward mammalian cells and can be utilized in antibacterial research.

KFA-027 is a HIV-1 inhibitor, with an IC50 of 0.398 nM. KFA-027 inhibits capsid-dependent early steps (reverse transcription, nuclear import, integration) and late-stage aberrant capsid assembly in the HIV-1 replication cycle. KFA-027 can be used for the study of multidrug-resistant HIV-1 infections.

EUK-189 is a synthetic superoxide dismutase (SOD) and catalase mimetic. EUK-189 can block oxygen/glucose deprivation (OGD)-induced ERK1/2 dephosphorylation, ATP depletion and eliminate ROS production. EUK-189 exhibits neuroprotective effect and can inhibit delayed radiation injury. EUK-189 can be used for the research of neurological disease, such as ischemic stroke.

ACBI-4 is a selective GTP-loaded active state of KRAS (KRAS(on)) PROTAC degrader. ACBI-4 has significant anti-proliferative effect and potently degrades multiple KRAS mutants in cancer cells, such as KRASG12R.

TP-110 is a proteasome inhibitor. TP-110 specifically inhibits the protease-like activity of the 20S proteasome, but does not affect the trypsin-like or peptidyl-glutamyl peptide hydrolysis activity. TP-110 inhibits the NF-κB pathway, activates caspase-8, -9, and -3, and causes PARP cleavage, significantly reducing the levels of cIAP-1 and XIAP. TP-110 causes cell cycle arrest at the G2/M phase and promotes apoptosis of cancer cells. TP-110 can be used in cancer research of prostate cancer and multiple myeloma, etc.